A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. (Q51348488)

4 April 2018

title

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. (English)

1 reference

4 April 2018

1 reference

C G Stott

1

1 reference

4 April 2018

L White

2

1 reference

4 April 2018

S Wright

3

1 reference

4 April 2018

D Wilbraham

4

1 reference

4 April 2018

G W Guy

5

1 reference

4 April 2018

publication date

22 November 2012

1 reference

4 April 2018

European Journal of Clinical Pharmacology

published in

1 reference

4 April 2018

volume

69

1 reference

4 April 2018

page(s)

1135-1147

1 reference

4 April 2018

issue

5

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.1007/s00228-012-1441-0

exact match

0 references

cites work

Therapeutic potential of cannabinoid receptor agonists as analgesic agents

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1441-0

A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood

21 January 2018

1 reference

12 December 2020

Quantitative measurement of Δ9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry

1 reference

12 December 2020

Cannabinoids and multiple sclerosis

1 reference

12 December 2020

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

1 reference

12 December 2020

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

1 reference

12 December 2020

10.1007/S00228-012-1441-0

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

23179176

1 reference

4 April 2018